Interest In Korean Biotech IPOs Dips Amid Year-End Rush
This article was originally published in PharmAsia News
Executive Summary
Bioventures seeking IPOs in the South Korean stock market are having a tough time due to waning interest from investors. A surge in such offerings this year, coupled with the usual IPO rush seen at the end of each year, have resulted in several biotech companies withdrawing plans or raising funds short of initial targets.